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ABSTRACT
Introduction Global population ageing is one of the key 
factors linked to the projected rise of dementia incidence. 
Hence, there is a clear need to identify strategies to 
overcome this expected health burden and have a 
meaningful impact on populations’ health worldwide. 
Current evidence supports the role of modifiable dietary 
and lifestyle risk factors in reducing the risk of dementia. 
In South- East Asia, changes in eating and lifestyle patterns 
under the influence of westernised habits have resulted 
in significant increases in the prevalence of metabolic, 
cardiovascular and neurodegenerative non- communicable 
diseases (NCDs). Low vegetable consumption and high 
sodium intake have been identified as key contributors 
to the increased prevalence of NCDs in these countries. 
Therefore, nutritional and lifestyle strategies targeting 
these dietary risk factors are warranted. The overall 
objective of this randomised feasibility trial is to 
demonstrate the acceptability of a dietary intervention 
to increase the consumption of high- nitrate green leafy 
vegetables and reduce salt intake over 6 months among 
Malaysian adults with raised blood pressure.
Methods and analysis Primary outcomes focus 
on feasibility measures of recruitment, retention, 
implementation and acceptability of the intervention. 
Secondary outcomes will include blood pressure, cognitive 
function, body composition and physical function (including 
muscle strength and gait speed). Adherence to the 
dietary intervention will be assessed through collection 
of biological samples, 24- hour recall and Food Frequency 
Questionnaire. A subgroup of participants will also 
complete postintervention focus groups to further explore 
the feasibility considerations of executing a larger trial, the 
ability of these individuals to make dietary changes and 
the barriers and facilitators associated with implementing 
these changes.
Ethics and dissemination Ethical approval has been 
obtained from Monash University Human Research Ethics 
Committee and Medical Research and Ethics Committee 
of Malaysia. Results of the study will be disseminated via 
peer- reviewed publications and presentations at national 
and international conferences.
TRIAL REGISTRATION NUMBER
ISRCTN47562685; Pre- results.
INTRODUCTION
Dementia is characterised by multiple cogni-
tive deficits and loss of independence, and 
its pathogenesis is linked to multiple distinct 
Strengths and limitations of this study
 ► Feasibility of the first 2×2 trial testing single and 
combined effects of dietary nitrate and salt reduc-
tion for the prevention of cognitive decline in devel-
oping countries.
 ► Longest high- nitrate- based intervention ever 
conducted.
 ► Use of objective biomarkers for the assessment of 
adherence to the dietary intervention and internal 
validation of the dietary assessment methods used 
(urinary sodium—24- hour urine vs spot urine/ni-
trate levels in blood—dried blood spots vs plasma 
and ELISA vs gold standard/nitrate in saliva—sali-
vary strip (point of care test) vs ELISA using saliva 
samples).
 ► Mixed- method approach to obtain key information 
on the feasibility of the dietary intervention.
 ► Owing to the small sample size and the feasibility 
nature of this study, the planned comparative anal-
ysis is only exploratory, and therefore, the efficacy 
of the intervention between groups cannot be de-
termined. However, the results of this study will be 
instrumental in the design and calculation of the 
sample size of a larger, follow- on efficacy trial.
 o
n
 August 27, 2020 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-035453 on 27 August 2020. Downloaded from 
2 McGrattan A, et al. BMJ Open 2020;10:e035453. doi:10.1136/bmjopen-2019-035453
Open access 
neuropathological processes including Alzheimer’s 
disease and/or vascular pathology.1 Several of the patho-
logical processes underlying dementia might be delayed, 
or prevented, by interventions focused on dietary and 
behavioural changes2 and, in the absence of definite 
pharmacological treatments, these options represent a 
key strategy to alleviate its individual and social impact.3 
Optimal control of modifiable cardiovascular factors, such 
as blood pressure, and adherence to lifestyle recommen-
dations have been consistently associated with reduced 
dementia risk in observational studies.2–4 The role of 
nutrition for dementia prevention has been extensively 
investigated by testing the role of single nutrients (ie, n-3 
Poly Unsaturated Fatty Acids or B vitamins5) or dietary 
patterns (ie, dietary approaches to stop hypertension 
(DASH) diet6 or Mediterranean diet7 8). There are a small 
number of randomised controlled trials (RCTs) available 
to support the effect of diet on cognition in mild cogni-
tive impairment9 and among those at risk of cognitive 
decline or cognitively healthy populations10; however, the 
trials have a small sample size and overall modest quality.
Malaysia is experiencing rapid socioeconomic and 
nutritional transitions.11 Changes in individual eating and 
lifestyle patterns and rise in food availability and financial 
prosperity of the population have resulted in significant 
increases in the prevalence of chronic metabolic, cardio-
vascular and neurodegenerative non- communicable 
diseases (NCDs).12 Effective public health interventions 
for the prevention of dementia are challenging in coun-
tries with limited social and healthcare resources which 
are unable to meet the growing demands of ageing popu-
lations. A systematic review of 22 RCTs investigated the 
effect of nutritional interventions on cognitive perfor-
mance in developing economies of East Asia, and the 
majority of the studies showed some significant benefi-
cial effects of the nutritional interventions on cognitive 
performance. However, these effects were not consistent 
across all of the neuropsychological tests used in each 
study.10 Therefore, there is a need for well- designed nutri-
tional intervention studies for the early prevention of 
cognitive decline and dementia.
Recent analyses have identified inorganic nitrate as 
a potential nutrient improving vascular and metabolic 
health.13 Beetroot and green leafy vegetables, such as 
spinach, lettuce and rocket, are a key source of natu-
rally available inorganic nitrate, containing over 250 mg 
of nitrate per 100 g of fresh vegetable weight.13 Inor-
ganic nitrate is closely linked to the metabolism of nitric 
oxide (NO) which is known for its multiple effects on 
physiological functions such blood pressure, brain func-
tion and immunity.14 An increase in inorganic nitrate 
consumption has been associated with an increase in 
NO production via complex mechanisms involving 
oral microbiota, gastric environment and activation of 
reducing enzymes.15 Recent epidemiological studies 
and clinical trials have demonstrated the association of 
increased nitrate intake with improved blood pressure, 
metabolic health and cognitive function.14 16 A 15- year 
prospective cohort study investigated the association 
of consumption of high- nitrate vegetables and risk of 
atherosclerotic vascular disease (ASVD) mortality. Results 
showed that a consumption of approximately 30 mg/day 
higher nitrate intake from vegetables was associated with 
a 21% lower risk of ASVD mortality. This nitrate amount 
equates to approximately 10–30 g/day of nitrate- rich 
vegetables.17 However, the impact on cognition is still 
unknown with studies of short intervention durations 
and among small samples, and limited studies conducted 
in developing countries.13 14 Nevertheless, with hyperten-
sion highlighted as an important modifiable risk factor 
for dementia,3 18 more studies that test the implementa-
tion of dietary interventions that aim to improve blood 
pressure are warranted.
Sodium is the main electrolyte contained in extracel-
lular fluids and involved in regulation of blood pressure 
and cellular activities. An excess sodium intake has been 
linked to extracellular volume expansion and increased 
blood pressure.19 The DASH diet has been specifically 
developed to promote consumption of healthy dietary 
choices alongside strictly controlled sodium intake.20 
Secondary analyses derived from seminal DASH studies 
showed additional benefits on blood pressure and 
cardiometabolic health in individuals with lower salt 
intake and adherence to a healthy dietary pattern.21 
These analyses have been extended to cognitive function 
with promising results,22 23 but the evidence has mostly 
come from studies conducted in the USA and no studies 
to our knowledge have been conducted in low/middle- 
income countries (LMICs). Epidemiological studies have 
repeatedly proven the association of high salt diets with 
impaired blood pressure control and increased cardio-
vascular risk24 25; this evidence has been confirmed in 
several clinical trials testing the effects of salt- reducing 
interventions and demonstrating the protective effects of 
salt reduction on cardiovascular health.26 27 A prospective 
study looked at the relationship between a reduction in 
salt intake with blood pressure, mortality from stroke and 
ischaemic heart disease (IHD).28 A decrease in salt intake 
by 1.4 g/day, as measured by 24- hour urinary sodium, 
contributed to a reduction in stroke and IHD mortality, 
and in addition, among individuals who were not on anti-
hypertensive medication, there was a significant fall in 
systolic blood pressure (SBP) of 2.7±0.34 mm Hg.28 Exces-
sive sodium consumption is recognised as a global health 
issue29 with efforts aiming to reduce salt intake at the 
population level by 30% by 2025. Seventy- five countries 
have already implemented national sodium reduction 
programmes to help meet this target.30
In sum, an increased consumption of dietary nitrate 
and lower salt intake may have additional benefits on 
health outcomes such as blood pressure and cognition, 
mediated by an increase in NO generation (ie, nitrate) 
and control of vascular tone and cellular metabolism (ie, 
sodium). However, this hypothesis has never been tested 
in previous interventions which represents the main 
aim of the feasibility study proposed in this protocol. 
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The Global Health Dementia Prevention and Enhanced 
Care (DePEC) project is a National Institute for Health 
Research (NIHR) funded study with a key goal to develop 
approaches for dementia prevention and develop more 
efficient postdiagnostic care in LMICs. The DePEC- 
Nutrition feasibility study (presented here) is one of five 
work streams within the overall DePEC project.
Purpose and aims
The overall objective of the DePEC- Nutrition feasibility 
study is to demonstrate the acceptability of a dietary inter-
vention to increase the consumption in high- nitrate green 
leafy vegetables and reduce salt intake over a 6- month 
period among Malaysian adults with raised blood pres-
sure. The objectives focus on the core areas of a trial that 
need to work for the study to succeed procedurally, such as 
recruitment ability and participant retention, data collec-
tion procedures and assessment methods used, potential 
to deliver the dietary intervention and resource require-
ment. Information on the effect size of the intervention 
on cognition and blood pressure will also be determined, 
which will be instrumental in the design and calculation 
of the sample size of a follow- on efficacy trial.
METHODS AND ANALYSIS
Study design
The DePEC- Nutrition feasibility study is a 6- month 
randomised 2×2 factorial trial including four parallel 
arms: (1) control, (2) high- nitrate vegetable consump-
tion, (3) low salt consumption and (4) combined high- 
nitrate vegetable consumption plus low salt consumption. 
The trial will be conducted among 120 middle- aged and 
older Malaysian adults. Sponsor and grant number: GHR 
Group: 16/137/62—NIHR Global Health Research 
Group on DePEC, Newcastle University, UK. The Stan-
dard Protocol Items: Recommendations for Interven-
tional Trials reporting guidelines were used to guide the 
preparation of this protocol.31
Participants
This study is embedded within the South East Asia 
Community Observatory (SEACO) population (http://
www. seaco. asia/). SEACO is a health and demographic 
surveillance site (HDSS); a unique research platform in 
population health and well- being focused on a middle- 
income community in Segamat, Johor in the southern 
tip of the Peninsular Malaysia. The district of Segamat 
comprises urban, rural and plantation areas with an ethnic 
mix including Malays, Chinese and Indian, in similar 
proportions to the national population. SEACO runs its 
HDSS research platform in five subdistricts (mukim) of 
the Segamat district: Bekok, Chaah, Gemereh, Jabi and 
Sungai Segamat. The SEACO population was established 
using a baseline census (March 2012 to February 2013) 
that included information on sociodemographic status 
and self- reported health conditions. Consenting partic-
ipants underwent detailed health profile assessments in 
the first health round in 2013–2014. The next census was 
done in 2017, with a total number of 40 015 participants 
completing the assessment. Individuals were seen again 
after 1 year (in 2018) for the second health round. Indi-
viduals aged 50 years and over, who are living in Segamat, 
Johor and have been assessed as part of SEACO during 
the health round in 2018 will form the study population 
for the DePEC- Nutrition feasibility study. The baseline 
assessment will be carried out in the Klink Kesihatans 
(KK) in Sungai Segamat subdistrict (a community health 
clinic in Segamat, Johor). Hence, only participants from 
within 5 km radius of KK Segamat will be included in the 
study population. A total of 2433 participants have been 
identified on the database as potentially eligible for this 
study by broad application of the study criteria (mean 
age (SD): 61.27 (6.77) years and number of men: n=1078 
(44.3%)). This subset of participants will be screened in 
detail, and then will be informed of the study and invited 
for a screening visit as outlined in the study procedures.
Recruitment
The community will be informed about this study via a 
local Community Engagement Committee who meet 
regularly to distribute information on projects planned 
within SEACO. Participants will be randomly identified by 
the application of the inclusion and exclusion criteria to 
the SEACO health surveillance database. Potential partic-
ipants will be approached via a home visit and will be 
provided with information about the study. They will be 
given an opportunity to read detailed information about 
the study procedures and can ask questions. Thereafter, 
their interest of participating in the study will be evalu-
ated. If they agree to take part, a screening assessment will 
be completed. If eligible, participants will be invited to 
attend a baseline study visit at the health facilities within 
the community.
Eligibility criteria
To be eligible for inclusion in this study, participants must 
report as:
1. Male and female participants with an age between 50 
and 75 years from the SEACO database.
2. Pre- hypertensive, stage 1 hypertensive or diagnosed 
hypertensive: any person with a self- reported history of 
hypertension (on or not on medication) or with elevat-
ed blood pressure (SBP 120–159 mm Hg or diastolic 
blood pressure (DBP) 80–99 mm Hg).
3. Not severely cognitively impaired (defined as a Mini 
Mental Examination Status (MMSE) Score of 19 or 
over).
Participants will be excluded from the study if they:
1. Are participating in other research clinical studies.
2. Are unable to provide consent.
3. Have SBP more than or equal to 160 mm Hg and/or 
DBP more than or equal to 100 mm Hg.
4. Adhere to any therapeutic diet such as weight loss 
treatments or a gluten- free diet.
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5. Are vegan (these individuals are likely to have a high 
intake of vegetables). Since Indian participants are 
more likely to follow a vegetarian or semi- vegetarian 
diet, in order to maintain representativeness across 
ethnic groups included in the study, only participants 
who are vegan will be excluded from the study.
6. Participants with a body mass index (BMI) less than 
18.5 kg/m2.
7. Have a history of active cancer or any diagnosis of 
cancer in the last 5 years.
8. Have a history of excessive alcohol intake (>21 units 
of alcohol per week).
9. Have a history of brain damage or significant head 
trauma (resulting in a loss of consciousness).
10. Have a diagnosis of acute and chronic medical con-
ditions interfering with the study outcomes such as 
systemic infections (tuberculosis, hepatitis B, HIV/
AIDS), severe liver and kidney diseases, inflammatory 
bowel diseases, coronary heart diseases, cerebrovas-
cular diseases or is a diabetic on insulin therapy.
11. Have had any major surgical procedures (in the past 
6 weeks or planned in the next year) that could inter-
fere with the study outcomes.
12. Have a current diagnosis of moderate or severe de-
pression, or other serious mental or brain disorder 
and/or are currently on psychiatric medication (anti-
depressants, sedatives, antipsychotics).
13. Regularly use sodium- altering drugs (ACE inhibi-
tors, angiotensin receptor blockers, corticosteroids, 
diuretics, hormonal therapies (oestrogens, thyroxin 
and progesterone), non- steroidal anti- inflammatory 
drugs, proton- pump inhibitors), organic nitrates.
14. Have changed their antihypertensive medication reg-
imen in the previous 3 months.
15. Have limited mobility due to any reason.
16. Are planning to move house within a year.
Study procedure
Data collection will be undertaken directly on an elec-
tronic hand held device (Samsung Galaxy Tab 3v—Survey 
CTO). Questionnaire items will be read out loud by the 
data collector, and participant responses will be recorded 
directly onto the electronic tablet. The flow of participants 
through the DePEC- Nutrition feasibility study is illus-
trated in figure 1. At the screening visit, written informed 
consent will be first obtained, after which participants 
will complete a screening questionnaire to collect infor-
mation on demographics, comorbidities, medication 
history, cognitive function (MMSE), body weight, height 
and resting blood pressure. If eligible, participants will 
undergo baseline assessments, consisting of two parts: a 
home visit (part 1), followed by an appointment at KK, 
Segamat (part 2). Baseline assessments will include: 
obtaining respondent’s signed informed consent for 
study participation, eligibility assessment (medical and 
medication history), dietary assessment (24- hour recall 
and Food Frequency Questionnaire (FFQ)), cognitive 
assessment, collection of biological samples (blood, dried 
blood spots, 24- hour urine and spot urine samples, saliva 
samples and salivary strips), measurements of hand grip 
and gait speed, physical activity (International Physical 
Activity Questionnaire (IPAQ)) and depression (Geri-
atric Depression Scale (GDS)).
An interim 2- month visit will take place for those in 
the intervention groups only, to provide reinforcement 
messages relating to the allocated dietary intervention 
and with a view to enhancing compliance with the inter-
vention. In addition, a brief adherence questionnaire will 
be administered, body weight and resting blood pressure 
will be measured and salivary strip and spot urine samples 
will be collected. The same measurements and further 
dietary reinforcement messages will be conducted at an 
interim 4- month visit for the participants allocated to the 
intervention arms. Participants in the control arm will 
only have one interim visit at month 4 and will have their 
weight and blood pressure measured. The end of study 
visit (at KK, Segamat) will include the conduction of the 
measurements collected at baseline, including cognitive 
assessment, dietary assessment and collection of biolog-
ical samples (blood, dried blood spots, 24- hour urine and 
spot urine samples, saliva samples, salivary strips). In addi-
tion, an exit group session (focus group evaluation) and 
a self- administered feedback questionnaire will be sched-
uled to evaluate the adherence to the interventions and 
obtain detailed feedback on the overall study protocol. 
Finally, the participants will be offered a token of appreci-
ation to acknowledge their participation in the study and 
to compensate for travel expenses. This is usually to the 
value of RM 25.
Figure 1 A flow diagram providing an overview of the study 
procedures.
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Randomisation and blinding
The SEACO health round database will serve as the 
sampling frame, from which eligible participants are 
identified. Block randomisation will be carried out to 
assign eligible participants into one of the four arms 
using R software (randomizeR).32 Block sizes of four 
participants will be used in the randomisation and will be 
generated by a member of the research team not involved 
in the data collection. The interviewers will be blinded to 
the participant assignment to intervention arms. Partic-
ipant blinding to the intervention allocation will not be 
possible due to the nature of the dietary intervention 
study. Matching of characteristics for group allocation will 
not be used in this study. The distribution of characteris-
tics, such as age or gender, will be part of the feasibility 
assessment to gain information on the characteristics of 
the population willing to participate without imposing 
any restrictions on the intention to participate in the 
study. This information will be used to evaluate whether 
specific randomisation approaches will need to be used in 
future studies to ensure even distribution of key charac-
teristics between groups.
Intervention and control arms
This dietary and behavioural intervention will focus 
on key components that are related to changing local 
dietary patterns influenced by nutritional transition 
trends in Malaysia. It aims to target two key components 
that have protective (dietary nitrate) and negative (salt 
intake) effects on cardiovascular and cognitive health. 
The intervention will target individuals with a higher 
Cardiovascular Disease (CVD) risk to adopt a tailored 
strategy to enhance daily consumption of green leafy 
vegetables and/or reduce salt intake. Nutritional coun-
selling sessions with a medical doctor will be conducted 
at baseline to provide sustainable and effective strategies 
to improve dietary habits as well as monitor and address 
key barriers to dietary change. These sessions will be 
delivered in a group setting using PowerPoint slides and 
practical activities to educate the group on the allocated 
dietary intervention. All intervention groups will receive 
written information focused on health benefits, sources, 
recommended intakes and practical tips related to one 
of the following dietary interventions: (1) to increase 
dietary nitrate, (2) to reduce salt intake and (3) to 
increase dietary nitrate and to reduce salt intake. Those 
who are randomised to the salt intervention (either 
alone or combined) will receive a measuring spoon as an 
additional strategy to support individuals to understand 
portion size and measure salt intake, as successfully tested 
by an intervention study in China.33 Furthermore, the 
Ministry for Health Malaysia set out in their Salt Reduc-
tion Strategy 2015–2020 how reducing the amount of 
salt and sauces consumed in the home is a key priority.34 
This provides justification for inclusion of the salt restric-
tion spoon as an intervention strategy. The intervention 
groups will also receive bi- weekly text message reminders 
to provide reinforcement of the key dietary behaviour 
change messages relevant for their group allocation. 
Compliance will be monitored during the intermediate 
visits (2 and 4 months, respectively) where participants 
will also receive reinforcement video messages to remind 
participants of the key dietary advice that was discussed 
during the counselling sessions at baseline. Those allo-
cated to the control group (4) will receive written infor-
mation on general healthy eating and lifestyle advice 
based on the Malaysian dietary guidelines.35
Outcome measures
Outcome assessments will be conducted at baseline, 
month 4 and month 6 for all groups, with an additional 
assessment visit at month 2 for those in the interven-
tion groups. Assessments at baseline and month 6 will 
be conducted in clinic/at home, with remaining assess-
ments completed in the participants own home. The 
same instruments will be used for measurements at each 
time point. Assessors are trained prior to the assessments 
to follow a standardised protocol. A timeline of the study 
procedures can be found in table 1.
Primary outcome
The primary outcome measures are related to feasibility 
and will be collected via questionnaire, review of the study 
procedures and by review of data collector field notes. 
Patient feedback, acceptance and adherence issues will 
be additionally assessed through qualitative focus groups 
conducted post intervention. The specific feasibility 
considerations that will be assessed in the study have been 
outlined in table 2. The CONSORT 2010 statement36 will 
be used to guide the reporting of the feasibility results.
Secondary outcomes
Cognitive assessment
A validated version of Montreal Cognitive Assessment test, 
auditory verbal learning test, categorical verbal fluency 
and trail making test part B will be conducted at baseline 
and end of study visits.
Blood pressure
Three consecutive measurements of resting blood pres-
sure readings will be recorded in a sitting position using 
a calibrated OMRON automated monitor (OMRON 
HEM 907, OMRON Healthcare, Milton Keynes, UK). 
The median measure will be used to estimate the blood 
pressure. Blood pressure will be measured at all outcome 
assessment visits.
Anthropometry and body composition
Body weight will be recorded in kilograms using cali-
brated, electronic scales to the nearest 0.1 kg where 
possible. Weight will be measured at all outcome assess-
ment visits. Height will be recorded in metres using a 
stadiometer and measured to the nearest 0.01 m where 
possible. The recordings for weight and height will be 
subsequently used to calculate BMI by dividing weight 
(kg) by height (m2). BMI will be calculated at baseline and 
end of study visits. Body composition will be measured 
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by bioelectrical impedance. A Tanita Body Composition 
analyser will be used to measure body fat percentage and 
classification, segmental subcutaneous fat and skeletal 
muscle percentage (whole body, trunk, legs and arms), 
resting metabolism, visceral fat level and classification 
and body age. Body composition will be measured at base-
line and end of study visits.
Physical assessments
The following physical assessments will be conducted 
at baseline and end of study visits. (1) Muscle strength 
will be measured by a hand grip- strength dynamometer. 
Using their right arm, the participant will be asked to 
make three measurements and an average calculated. 
The same process will be repeated for the left arm. (2) 
A 4- metre walk test will be done to assess the gait speed. 
Two trials will be conducted and the average measure 
of time in minutes will be used to assess the gait speed. 
(3) In the Timed Up and Go (TUG) test, the time taken 
for participants to rise from an armless chair (46 cm 
height), to walk 3 m, turn, walk back and sit down will 
be measured. The TUG test will be performed two times 
consecutively, and the average of the two scores will be 
used. (4) The GDS will be used to assess depressive symp-
toms37—scores range from 0 to 15, with a score of 0 to 
5 indicating a normal score and a score greater than 5 
suggesting depression. The IPAQ38 will be used to assess 
physical activity.
Dietary assessment
Conventional approaches to assessing dietary intake are 
associated with measurement error. There is a growing 
consensus that combining the use of self- report instru-
ments (like FFQ and 24- hour recall) together with 
biomarker analyses could increase the accuracy of 
individual intake estimates, especially for episodically 
consumed foods.39 40 Thus, dietary assessment data will be 
collected by two methods: 24- hour recall and FFQ. Partic-
ipants will complete a 1- day 24- hour recall facilitated by 
a trained data collector. The FFQ is a validated question-
naire used in previous dietary research in Malaysia.41 
Information will be entered into Nutritionist Pro Soft-
ware (V.7.5) and daily intake will be calculated.
Biological sample collection
The following bio- specimen will be collected in this study:
1. Whole venous blood (15 mL).
2. Twenty- four- hour urine sample.
3. Spot urine sample.
4. Saliva.
5. Capillary blood.
All samples will be used only for the purpose of the 
study. The venous blood will first be centrifuged, sepa-
rated into aliquots and then stored at −20°C at the KK 
Segamat and then transported to Monash University 
Sunway campus for storage. Other samples will be stored 
at −20°C storage. The freezer room for the stored samples 
will be under lock and key with restricted access.P
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Blood sampling
Whole blood samples will be analysed to measure changes 
in nitrite concentrations during the intervention. Samples 
will also be analysed to assess for biomarkers of cardio-
vascular risk (C reactive protein, glycated haemoglobin, 
nitro- tyrosine) and direct brain measures such as plasma 
brain- derived neurotrophic factor (BDNF), plasma 
amyloid β42 and amyloid β40. A capillary blood sample will 
be taken and analysed for the concentration of glucose in 
the blood using a portable glucometer. Dried blood spot 
samples will be analysed to measure changes in nitrate 
concentrations during the intervention. Blood spots will 
be first processed using a standardised elution protocol to 
obtain a liquid solution of the samples and then analysed 
for nitrate concentrations using ozone- based chemilumi-
nescence, which is the reference method for the analysis 
on nitrate in biological fluids. All blood sampling assess-
ment methods will be conducted at baseline and end of 
study visits. Venous blood samples will be performed by a 
qualified medical attendant or staff nurse practising at KK 
Segamat and dried blood spot samples will be collected 
by a trained data collector.
Twenty-four hour urine and spot urine sampling
Both 24- hour urine and spot urine samples will be 
collected. Twenty- four- hour urine collection has been 
associated with a having high respondent burden owing 
to the time consuming nature of this method, particularly 
in a community and LMIC setting, where 24- hour urine 
sampling may be logistically difficult. Spot urine sampling 
is potentially a more convenient and affordable alterna-
tive. However, there are still a number of questions about 
the reliability of spot urine collection as a means of moni-
toring intervention adherence. Therefore, by using these 
two methods of urine collection, the authors hope to 
explore the feasibility of implementing these collection 
methods within the target population.42
Eligible participants will be provided with a kit to collect 
a 24- hour urine sample during their baseline home visit 
(part 1). This will be provided 2 days before their clinic 
visit (part 2). The kit includes: (1) a participant informa-
tion booklet with written instructions on how to collect 
the sample; (2) a ‘24- hour urine collection record’ to 
note essential information about the urine collection; (3) 
urine- collecting equipment: (a) 2.5- litre screw- capped 
plastic container for storing the 24- hour urine sample, 
(b) 1- litre plastic jug which the urine will be voided into, 
(c) 1- litre screw- capped plastic container either as backup 
container when the 2.5- litre storage container is full, or 
for temporal collections of urine made outside the home 
and (4) a permanent marker pen to note the start and 
Table 2 Primary outcome: feasibility considerations to be assessed
Feasibility considerations
Recruitment 1. Recruitment rates
2. Time taken for the recruitment of participants
3. Characteristics of recruited sample as against expected
4. Non- response rates
5. Reasons for non- response
Retention and completion 1. Retention rates
2. Number of drops and reasons for withdrawal
3. Follow- up response rates (2 months and 4 months follow- ups)
Feasibility of measurement tools 1. Time taken to fill in questionnaires
2. Missing data from questionnaires
3. Understanding level of procedures and measurement protocols
4. Suitability of outcome measures
5. Sensitivity of outcome measures to change
6. Internal consistency of outcome measures—validation of data collection methods 
(24 hours vs spot urine; saliva samples vs salivary strips)
Resource capacity 1. Data collection and measurement equipment
2. Field support (transportation, IT and so on)
3. Personnel (were the right numbers of people with the right skills available when they 
were needed)
4. Duration of each phase
Acceptability and adherence to 
intervention
1. Barriers to participation (collected at screening interview)
2. Burden (reasons for not taking part/discontinuation or dropping out)
3. Qualitative enquiry/feedback from participants and research staff
4. Focus group evaluation—this part of the feasibility trial will separately examine the 
acceptability and suitability of: intervention materials; intervention timing; intervention 
procedures; measurement and sample collection; adherence to intervention and 
barriers and facilitators to dietary and lifestyle changes
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finish times of urine collection in the 2.5- litre container. 
Trained data collectors will verbally explain the method 
of 24- hour urine collection to participants. The 24- hour 
urine collection will be initiated 1 day before their clinic 
visit and end in the morning of their appointment. Partic-
ipants will also collect a spot urine sample on the morning 
of their clinic visit. They will be provided with a 60 mL 
screw- capped plastic bottle for the spot urine collection. 
Participants will be instructed by a trained data collector 
to provide a spot urine sample using the midstream clean- 
catch technique.
The 24- hour urine samples collected will be assessed for 
completeness using assessment of the duration of urine 
collection, the total urine volume and 24- hour urinary 
creatinine excretion. The urine samples will be excluded 
from analysis if the time of the collection falls outside the 
range of 22–26 hours, if the total 24- hour urine volume is 
less than 500 mL or greater than 6000 mL and if 24- hour 
creatinine excretion is less than 3 mmol or greater than 
25 mmol in women, or less than 6 mmol or greater than 
30 mmol in men. Urinary sodium will be determined 
using the ion‐selective electrode method. For nitrate, 
samples will be diluted 1:100 and then analysed for nitrate 
concentrations using ozone- based chemiluminescence, 
which is the reference method for the analysis on nitrate 
in biological fluids.
Saliva sampling
Whole saliva will be collected using the passive drool 
technique. One millilitre of which will be collected into 
one collection tube. Participants will be asked to generate 
some saliva in their mouth and when ready, the partic-
ipant should hold the adaptor with collection tube 
attached to their mouth and pass saliva into the tube. This 
process is repeated until desired amount is collected. To 
measure nitrate, samples will be diluted 1:100 and then 
analysed for nitrate concentrations using ozone- based 
chemiluminescence. For the salivary strips, a dedicated 
app freely available to download on mobile devices will 
be used to provide a quantitative reading of the salivary 
nitrite concentrations as a surrogate marker of dietary 
nitrate intake.
Patient and public involvement—post intervention qualitative 
evaluation
Participants will be invited to provide feedback on their 
participation in the intervention study via focus groups 
discussions. The focus group topic guide will also be piloted 
among a random sample of participants prior to imple-
mentation to allow feedback, refinement and tailoring 
prior to implementation. Two focus group discussions will 
be conducted within each arm of trial (total 8). Purposive 
sampling will be used to capture broad variation in age, 
ethnicity, house location and for better understanding of 
the phenomenon being studied. All focus groups discus-
sions will be audio recorded and the topics covered will 
include: (1) access to the food items—financial (afford-
ability), physical factors; (2) cultural acceptability of the 
recommended food items; (3) family support to adhere 
to the dietary changes; (4) adherence to the instruc-
tions—facilitators and barriers, methods to self- monitor; 
(5) perceived benefit and side effects of intervention; 
(6) study context—education material, frequency of 
visit, location of visits, data collection methods and tools; 
(7) provision of biomedical samples—barriers, cultural 
acceptability, difficulty; (8) likes and dislikes in relation 
to the new dietary options and (9) preferred intervention 
arm. Finally, a behaviour change theoretical framework 
will be used to guide the qualitative analysis.43 44 This will 
allow the feedback and recommendations from partici-
pants to directly inform refinements and tailoring of the 
intervention for a follow- on efficacy trial as well as to 
understand the barriers and facilitators to dietary change 
among this target group.
Sample size
A formal sample size calculation has not been performed 
considering the pilot, feasibility nature of the study. A 
sample size of 30 per group was based on the estimated 
effect size provided by the guidelines by Whitehead et al,45 
which outlines the sample size calculation for pilot studies 
with the aim to maximise resources and avoid occurrence 
of a type II error. Specifically, a sample size of greater than 
25 individuals per group would provide in a 90% powered 
main trial the ability to detect a small effect size between 
0.1 and 0.3. More than 100 participants are expected to 
complete the trial; that is, an anticipated drop- out rate 
≤20%.
Statistical analysis
As the main aims of this feasibility study relate to the feasi-
bility, acceptability and the potential to deliver a dietary 
intervention, these data will be reported narratively illus-
trated with descriptive statistics. The CONSORT 2010 
statement will be used to guide the reporting of this infor-
mation.36 Secondary aims are largely descriptive, aiming 
to provide bounds for key parameters to inform the main 
trial. Intention- to- treat analysis will be used to include all 
randomised participants and determine the key outcome 
measures. The recruitment and retention rate in each 
arm will be described. It is unlikely that statistically signif-
icant differences in retention rates will be discovered, but 
upper and lower bounds will be estimated and reasons 
for groups with apparently low recruitment or retention 
rates will be explored qualitatively. Normality of the distri-
bution of the variables and appropriate transformations 
(LogX, 1/X, Xn) will be performed if necessary. Summary 
data will be expressed as mean (SD) or frequency (%). 
General linear models for repeated measures will be used 
to detect significant differences between the intervention 
groups with and without adjustment for baseline levels. χ2 
test will be used for categorical variables. An interaction 
term (time×group) will be built to assess between- group 
interactions in changes in the measured outcomes during 
the interventions. Dietary data will be analysed using the 
Nutritionist Pro Software (V.7.5).
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Data collection supervision and training
SEACO is an ISO- certified research platform for its opera-
tions, therefore training and supervision are carried out in 
accordance with SEACO’s standard operating procedures. 
All data collectors are required to be fluent in the local 
language (Bahasa Melayu or Malay language or Mandarin) 
and have at least a working knowledge of English. To 
ensure data quality and consistency across interviewers, 
the field supervisor will undertake random concurrent 
supervisory visits to observe practice. The data collectors 
will also be periodically observed by the project leader and 
the field manager. Based on the scoring completed during 
these observation sessions, onsite training or re- training 
will be carried out as appropriate. Data collection is under-
taken on Samsung Galaxy tablets. The data are encrypted 
on the tablet to ensure they are secure and inaccessible in 
the unlikely event that they are mislaid by data collectors. 
Transfer of data from the tablet to the remote server is done 
on a weekly basis. The data are also encrypted on the server 
and backed up by servers at Monash Sunway Campus and 
at Monash Clayton. Research staff have limited access to 
anonymised data.
Data monitoring
All expected and unexpected adverse events reported by 
participants will be recorded in an events register and 
reported to the Human Research Ethics Committee. Due 
to the nature of the treatment products, that is, commer-
cially available food products, no adverse events are 
expected. However, if participants feel in anyway adversely 
affected by any foods or the principal investigator feels an 
adverse event necessitates cessation, the participant would 
be advised not to continue and the appropriate measures 
will be taken (ie, record in field notes, contact research 
nurse and principal investigator if deemed necessary).
Ethics and dissemination
The procedures outlined in this protocol, pertaining to 
the conduct, evaluation and documentation of this study 
are designed to ensure that the sponsor and investigator 
abide by Good Clinical Practice (GCP) Guidelines and 
under the guiding principles detailed in the Declaration 
of Helsinki. DM and YCS have obtained GCP certification 
from Ministry of Health, Malaysia. Ethical approval has 
been granted by Monash University Human Research 
Ethics Committee (17864) and the Malaysian Medical 
Research Ethics Committee (#NMRR-19-617-45916). 
Results of the study will be disseminated via peer- reviewed 
publications and presentations at national and interna-
tional conferences.
DISCUSSION
This study will demonstrate the feasibility of a dietary 
intervention to increase the consumption of high- nitrate 
green leafy vegetables and reduce salt intake over a 
6- month period among Malaysian adults with raised 
blood pressure. The design of this feasibility study has 
taken into account the evidence collected in developed 
countries on the efficacy of complex interventions for 
the prevention of cognitive decline and evidence on the 
major transitions in dietary patterns occurring in devel-
oping countries as a result of nutrition transition trends. 
An increased consumption of vegetables and reduction 
of salt intake are key dietary recommendations for the 
prevention of cardiometabolic diseases. Our hypotheses 
are that a targeted, educational approach, to encourage 
healthy dietary choices focused on these key elements of 
the diet, would be linked to greater long- term adherence 
to the interventions and improved cognitive function 
with prospective, projected reduced risk of dementia in 
these populations. This mixed- method feasibility study 
will provide key quantitative and qualitative information 
on the delivery of a novel dietary intervention and will 
aim to estimate the effect size of the single and combined 
interventions on cognitive function and blood pressure, 
which will be instrumental in the design and calculation 
of the sample size of a larger, follow- on efficacy trial.
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